Literature DB >> 9564199

Objective and subjective measures of the pharmacodynamic effects of Adderall in the treatment of children with ADHD in a controlled laboratory classroom setting.

J Swanson1, S Wigal, L Greenhill, R Browne, B Waslick, M Lerner, L Williams, D Flynn, D Agler, K L Crowley, E Fineberg, R Regino, M Baren, D Cantwell.   

Abstract

In a randomized double-blind crossover study of children with attention deficit hyperactivity disorder (ADHD), the time course effects of four doses of Adderall (5, 10, 15, and 20 mg) and an inactive (placebo) control, and an active (Ritalin) control were evaluated. A laboratory classroom setting was established in which subjective (teacher ratings of deportment and attention) and objective (scores on math tests) measurements were taken every 1.5 hours across the day. In addition to significant time and dose effects of Adderall, significant time-of-day effects were documented in the placebo condition for the subjective measure of deportment and objective measures of performance. Regression analyses were used to estimate the magnitude of these baseline effects. Correlations across time were used to evaluate the test-retest reliability of each measure in the face of these time-dependent placebo effects. After placebo/time adjustments, within-subject correlations between pairs of measures were used to evaluate the validity of the math test as a measure of response to stimulant medication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564199

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  9 in total

1.  Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder.

Authors:  David W Goodman
Journal:  P T       Date:  2010-05

2.  Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

Authors:  Frank Lopez; Raul Silva; Linda Pestreich; Rafael Muniz
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

3.  Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome.

Authors:  Robyn L Powers; David J Marks; Carlin J Miller; Jeffrey H Newcorn; Jeffrey M Halperin
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-10       Impact factor: 2.576

4.  A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.

Authors:  Matthew Brams; Rafael Muniz; Ann Childress; John Giblin; Alice Mao; John Turnbow; Mary Borrello; Kevin McCague; Frank A Lopez; Raul Silva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies.

Authors:  Anna C Shier; Thomas Reichenbacher; Harinder S Ghuman; Jaswinder K Ghuman
Journal:  J Cent Nerv Syst Dis       Date:  2012-12-20

Review 6.  Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.

Authors:  David Coghill; Tobias Banaschewski; Alessandro Zuddas; Antonio Pelaz; Antonella Gagliano; Manfred Doepfner
Journal:  BMC Psychiatry       Date:  2013-09-27       Impact factor: 3.630

7.  A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder.

Authors:  Greg Mattingly; Valerie Arnold; Brian Yan; Ming Yu; Brigitte Robertson
Journal:  J Child Adolesc Psychopharmacol       Date:  2020-10-13       Impact factor: 2.576

Review 8.  Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).

Authors:  Ole Jakob Storebø; Erica Ramstad; Helle B Krogh; Trine Danvad Nilausen; Maria Skoog; Mathilde Holmskov; Susanne Rosendal; Camilla Groth; Frederik L Magnusson; Carlos R Moreira-Maia; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Bente Forsbøl; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-11-25

9.  Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data.

Authors:  Edmund J S Sonuga-Barke; James M Swanson; David Coghill; Heleen H DeCory; Simon J Hatch
Journal:  BMC Psychiatry       Date:  2004-09-30       Impact factor: 3.630

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.